Metraipolis › archive › dc_4926d260ae4b
Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for… — Europe PMC PMID:42212134
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42212134
- DOI
- 10.3389/fimmu.2026.1817221
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T09:55:21.418Z
- SHA-256 of the archived text
07afbfc310a9595ef88f7cd8a04106d1a30a3f2922fcca0cc69d263b2c5e579c- Stable URL of this page
https://metraipolis.com/documento/dc_4926d260ae4b
How to cite
Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for… — Europe PMC PMID:42212134 — Europe PMC (en), https://europepmc.org/article/MED/42212134 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4926d260ae4b (Metraipolis archive dc_4926d260ae4b, sha256 07afbfc310a9595ef88f7cd8a04106d1a30a3f2922fcca0cc69d263b2c5e579c)
BibTeX
@misc{dc4926d260ae4b,
title = {Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for… — Europe PMC PMID:42212134},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42212134},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4926d260ae4b; sha256 07afbfc310a9595ef88f7cd8a04106d1a30a3f2922fcca0cc69d263b2c5e579c},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42212134. Agents can read the archived copy with the MCP tool read_document.